Genética Avanzada DNActive was born in late 2015 by Juan Antonio Martínez Fiestas, with the mission of democratising genetic information among the population.
This Granada-based startup is capable of determining a person’s susceptibility to many of the most common illnesses and pathologies through a personalised genetic study. Since the end of last year, the company began marketing specific solutions in the clinical sphere, with their Pharmacogenetic analysis and Genetic Risk Map across three variables: Global, common illnesses and paediatrics.
This tool analyses the risk of suffering illnesses such as diabetes, coeliac disease and osteoporosis through a personalised genetic study that consists of creating prevention plans, nutritional plans, adapted training and tailored supplements, which allows the patient to prevent the emergence of these pathologies to mitigate the symptoms.
For its launch to market, DNActive has gone through three subsidised capital extensions, participative loans, ordinary long-term loans and short-term loans, with a total sum of 1 million euros over the last 3 years and half the life of the society. As its main objective for the end of the year, the company aims to consolidate its position and close with sales of 800 thousand euros and, therefore, by 2020 it can embark on strong sales growth and consolidation of its position in the international markets where it’s present.